Targeting m6A writer METTL3 with engineered nanovesicles to suppress neuroinflammation
Abstract
Epigenetic editing, particularly N6-methyladenosine (m⁶A) modification, represents a promising therapeutic strategy by silencing genes without altering DNA sequence. However, in vivo epigenetic intervention of neuroinflammation remains challenging and has rarely been explored. Here we developed a hybrid epigenetic nanomodulator, siMETTL3-hNVs, by integrating natural microglia-derived nanovesicles (NVs) with synthetic liposomes pre-loading small interfering RNA targeting the m6A writer methyltransferase-like 3 (METTL3). Natural NVs enabled siMETTL3-hNVs to achieve inflamed-brain delivery through CCR2-CCL2 chemotaxis and caveolae-mediated transcytosis across the blood-brain barrier. More importantly, relying on abundant cytokine receptors on the NVs, siMETTL3-hNVs served as decoys to neutralize pro-inflammatory cytokines, synergizing with the intracellular silencing of METTL3 to drive microglial M2 repolarization. In mouse models of acute neuroinflammation and radiation-induced brain injury, siMETTL3-hNV treatment significantly reduced cytokine levels, attenuated hippocampal damage, and ameliorated cognitive deficits. This work overcomes critical delivery bottlenecks in m6A-based therapeutics and establishes a robust strategy for epigenetic reprogramming of neuroinflammation.
References
1. F.D. Shi & Yong, V.W. Neuroinflammation across neurological diseases. Science 388, eadx0043 (2025).
2. G. Castellani, Croese, T., Peralta Ramos, J.M. & Schwartz, M. Transforming the understanding of brain immunity. Science 380, eabo7649 (2023).
3. Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). Alzheimers Dement 9, 714-723 (2013).
4. M.T. Heneka, et al. Neuroinflammation in Alzheimer disease. Nat. Rev. Immunol. 25, 321-352 (2025).
5. Y. Fu, Liu, Q., Anrather, J. & Shi, F.D. Immune interventions in stroke. Nat. Rev. Neurol. 11, 524-535 (2015).
6. D. Jakimovski, et al. Multiple sclerosis. Lancet 403, 183-202 (2024).
7. J. Li, Mao, N., Wang, Y., Deng, S. & Chen, K. Novel insights into the ROCK-JAK-STAT signaling pathway in upper respiratory tract infections and neurodegenerative diseases. Mol. Ther. 33, 32-50 (2025).
8. P.R. Ho, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol. 16, 925-933 (2017).
9. S.L. Hauser, et al. Ocrelizumab versus Interferon Beta-1a in relapsing multiple sclerosis. N. Engl. J. Med. 376, 221-234 (2017).
10. M. Frye, Harada, B.T., Behm, M. & He, C. RNA modifications modulate gene expression during development. Science 361, 1346-1349 (2018).
11. P. Mathiyalagan, et al. FTO-dependent N6-methyladenosine regulates cardiac function during remodeling and repair. Circulation 139, 518-532 (2019).
12. H. Shi, Wei, J. & He, C. Where, when, and how: context-dependent functions of RNA methylation writers, readers, and erasers. Mol. Cell 74, 640-650 (2019).
13. D. Merkurjev, et al. Synaptic N6-methyladenosine (m6A) epitranscriptome reveals functional partitioning of localized transcripts. Nat. Neurosci. 21, 1004-1014 (2018).
14. S. Su, et al. Cryo-EM structures of human m6A writer complexes. Cell Res. 32, 982-994 (2022).
15. F. Zhao, et al. METTL3-dependent RNA m6A dysregulation contributes to neurodegeneration in Alzheimer's disease through aberrant cell cycle events. Mol. Neurodegener. 16, 70 (2021).
16. X. Wu, et al. The m6A methyltransferase METTL3 drives neuroinflammation and neurotoxicity through stabilizing BATF mRNA in microglia. Cell Death Differ. 32, 100-117 (2025).
17. C. Miller, et al. Pathological α-synuclein dysregulates epitranscriptomic writer METTL3 to drive neuroinflammation in microglia. Cell Reports 44, 115618 (2025).
18. M. Yan, et al. SOCS modulates JAK-STAT pathway as a novel target to mediate the occurrence of neuroinflammation: Molecular details and treatment options. Brain Res. Bull. 213, 110988 (2024).
19. H. Qin, et al. Signal transducer and activator of transcription-3/suppressor of cytokine signaling-3 (STAT3/SOCS3) axis in myeloid cells regulates neuroinflammation. Proc. Natl. Acad. Sci. U. S. A. 109, 5004-5009 (2012).
20. H.B. Li, et al. m(6)A mRNA methylation controls T cell homeostasis by targeting the IL-7/STAT5/SOCS pathways. Nature 548, 338-342 (2017).
21. L. Cai, et al. ALKBH5 demethylates the m(6)A modification of SOCS3 in microglia/macrophages and alleviates neuroinflammation after brain injury. Proc. Natl. Acad. Sci. U. S. A. 122, e2504697122 (2025).
22. K. Paunovska, Loughrey, D. & Dahlman, J.E. Drug delivery systems for RNA therapeutics. Nat. Rev. Genet. 23, 265-280 (2022).
23. E.I. Buzas. The roles of extracellular vesicles in the immune system. Nat. Rev. Immunol. 23, 236-250 (2023).
24. E.L.A. S, Mäger, I., Breakefield, X.O. & Wood, M.J. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat. Rev. Drug Discov. 12, 347-357 (2013).
25. I.K. Herrmann, Wood, M.J.A. & Fuhrmann, G. Extracellular vesicles as a next-generation drug delivery platform. Nat. Nanotechnol. 16, 748-759 (2021).
26. K.W. Witwer & Wolfram, J. Extracellular vesicles versus synthetic nanoparticles for drug delivery. Nat. Rev. Mater. 6, 103-106 (2021).
27. J. Ren, et al. Schwann cell-derived exosomes containing MFG-E8 modify macrophage/microglial polarization for attenuating inflammation via the SOCS3/STAT3 pathway after spinal cord injury. Cell Death Dis. 14, 70 (2023).
28. K. Ge, et al. Engineering EVs-mediated mRNA delivery regulates microglia function and alleviates depressive-like behaviors. Adv. Mater. 37, e2418872 (2025).
29. R. Molinaro, et al. Biomimetic proteolipid vesicles for targeting inflamed tissues. Nat. Mater. 15, 1037-1046 (2016).
30. M. Mathieu, Martin-Jaular, L., Lavieu, G. & Théry, C. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat. Cell Biol. 21, 9-17 (2019).
31. L. Rao, et al. Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines. Proc. Natl. Acad. Sci. U. S. A. 117, 27141-27147 (2020).
32. Q.F. Meng, et al. Inhalation delivery of dexamethasone with iSEND nanoparticles attenuates the COVID-19 cytokine storm in mice and nonhuman primates. Sci. Adv. 9, eadg3277 (2023).
33. W. Gu, et al. Extracellular vesicles incorporating retrovirus-like capsids for the enhanced packaging and systemic delivery of mRNA into neurons. Nat. Biomed. Eng. 8, 415-426 (2024).
34. Y. Gu, et al. Engineering hybrid nanoparticles for targeted codelivery of triptolide and CYP3A4-siRNA against pulmonary metastatic melanoma. Sci. Adv. 11, eadv6990 (2025).
35. A. Hoshino, et al. Tumour exosome integrins determine organotropic metastasis. Nature 527, 329-335 (2015).
36. M. Piffoux, Silva, A.K.A., Wilhelm, C., Gazeau, F. & Tareste, D. Modification of Extracellular Vesicles by Fusion with Liposomes for the Design of Personalized Biogenic Drug Delivery Systems. ACS Nano 12, 6830-6842 (2018).
37. S.H. Yoon, et al. Microglial NLRP3-gasdermin D activation impairs blood-brain barrier integrity through interleukin-1β-independent neutrophil chemotaxis upon peripheral inflammation in mice. Nat. Commun. 16, 699 (2025).
38. J. El Khoury, et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat. Med. 13, 432-438 (2007).
39. Z. Shi, et al. Microglia drive transient insult-induced brain injury by chemotactic recruitment of CD8+ T lymphocytes. Neuron 111, 696-710.e699 (2023).
40. Y. Gao, et al. A self-directed Trojanbot-enzymatic nanobot in neutrobot for active target therapy of glioblastoma. Nat. Commun. 16, 5263 (2025).
41. G.C. Terstappen, Meyer, A.H., Bell, R.D. & Zhang, W. Strategies for delivering therapeutics across the blood-brain barrier. Nat. Rev. Drug Discov. 20, 362-383 (2021).
42. M. Sousa de Almeida, et al. Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine. Chem. Soc. Rev. 50, 5397-5434 (2021).
43. C. Wang, et al. Blood-brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system. Nat. Mater. 24, 1653-1663 (2025).
44. Z. Wang, et al. A sphingolipid-derived paclitaxel nanovesicle enhances efficacy of combination therapies in triple-negative breast cancer and pancreatic cancer. Nat. Cancer 6, 1734-1753 (2025).
45. S. Chatterjee, Kon, E., Sharma, P. & Peer, D. Endosomal escape: A bottleneck for LNP-mediated therapeutics. Proc. Natl. Acad. Sci. U. S. A. 121, e2307800120 (2024).
46. A. Carrillo-Jimenez, et al. TET2 Regulates the Neuroinflammatory Response in Microglia. Cell Rep. 29, 697-713.e698 (2019).
47. M. Datta, et al. Histone Deacetylases 1 and 2 Regulate Microglia Function during Development, Homeostasis, and Neurodegeneration in a Context-Dependent Manner. Immunity 48, 514-529.e516 (2018).
48. C.N. Parkhurst, et al. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell 155, 1596-1609 (2013).
49. N.R. Johnson, et al. CSF1R inhibitors induce a sex-specific resilient microglial phenotype and functional rescue in a tauopathy mouse model. Nat. Commun. 14, 118 (2023).
50. J. Bové, et al. BAX channel activity mediates lysosomal disruption linked to Parkinson disease. Autophagy 10, 889-900 (2014).
51. R. Scholz, Brösamle, D., Yuan, X., Beyer, M. & Neher, J.J. Epigenetic control of microglial immune responses. Immunol. Rev. 323, 209-226 (2024).
52. T. Bartels, De Schepper, S. & Hong, S. Microglia modulate neurodegeneration in Alzheimer's and Parkinson's diseases. Science 370, 66-69 (2020).
53. T. Chelmicki, et al. m6A RNA methylation regulates the fate of endogenous retroviruses. Nature 591, 312-316 (2021).
54. X.Q. Gao, et al. The piRNA CHAPIR regulates cardiac hypertrophy by controlling METTL3-dependent N6-methyladenosine methylation of Parp10 mRNA. Nat. Cell Biol. 22, 1319-1331 (2020).
55. A.V. Villarino, Kanno, Y. & O'Shea, J.J. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat. Immunol. 18, 374-384 (2017).
56. X. Han, et al. RNA m6A methylation modulates airway inflammation in allergic asthma via PTX3-dependent macrophage homeostasis. Nat. Commun. 14, 7328 (2023).
57. J.J. Babon, et al. Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity. Immunity 36, 239-250 (2012).
58. M.L. Monje, Mizumatsu, S., Fike, J.R. & Palmer, T.D. Irradiation induces neural precursor-cell dysfunction. Nat. Med. 8, 955-962 (2002).
59. J.E. Baulch, et al. Cranial grafting of stem cell-derived microvesicles improves cognition and reduces neuropathology in the irradiated brain. Proc. Natl. Acad. Sci. U. S. A. 113, 4836-4841 (2016).
60. Z. Zhang, et al. Pregabalin mitigates microglial activation and neuronal injury by inhibiting HMGB1 signaling pathway in radiation-induced brain injury. J. Neuroinflammation 19, 231 (2022).
61. A.D. Nahmad, et al. Frequent aneuploidy in primary human T cells after CRISPR-Cas9 cleavage. Nat. Biotechnol. 40, 1807-1813 (2022).
62. F. Tremblay, et al. A potent epigenetic editor targeting human PCSK9 for durable reduction of low-density lipoprotein cholesterol levels. Nat. Med. 31, 1329-1338 (2025).
63. C. Hou, et al. METTL1-mediated m7G methylation of Sarm1 mRNA promotes macrophage inflammatory responses and multiple organ injury. Sci. Immunol. 10, eadv4810 (2025).
64. J. Zhao, et al. Brain 5-hydroxymethylcytosine alterations are associated with Alzheimer's disease neuropathology. Nat. Commun. 16, 2842 (2025).
65. S. Kamerkar, et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature 546, 498-503 (2017).
66. P. Zhang, et al. Genetically engineered liposome-like nanovesicles as active targeted transport platform. Adv. Mater. 30, 1705350 (2018).
67. E. Di Ianni, Obuchi, W., Breyne, K. & Breakefield, X.O. Extracellular vesicles for the delivery of gene therapy. Nat. Rev. Bioeng. 3, 360-373 (2025).
68. Xu, L. Custom code for sequencing data analysis in “Targeting m6A writer METTL3 with engineered nanovesicles to suppress neuroinflammation”. Zenodo. https://doi.org/10.5281/zenodo.20627531 (2026).
Metrics
DOI:
Submission ID:
Downloads
Posted
Versions
- 2026-06-16 (2)
- 2026-06-16 (1)
How to Cite
Download Citation
Declaration of Competing Interests
The authors declare no competing interests to disclose.
Copyright
The copyright holder for this preprint is the author/funder.
All rights reserved. This work is protected by copyright. No part of this work may be reproduced, distributed, or transmitted in any form or by any means without the prior written permission of the copyright holder.